Recursion Pharmaceuticals ( (RXRX) ) has shared an update.
On March 18, 2025, Recursion Pharmaceuticals announced the appointment of Dr. Namandjé Bumpus and Elaine Sun to its Board of Directors, effective March 15, 2025. Dr. Bumpus, with her extensive experience in scientific innovation and regulatory strategy from her tenure at the FDA, and Ms. Sun, with her leadership in life sciences finance and corporate strategy, are expected to significantly contribute to Recursion’s growth and strategic direction. This move is seen as a strengthening of the company’s leadership as it continues to expand its clinical pipeline and enhance its platform, potentially impacting its operations and market position positively.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical stage TechBio company focused on decoding biology to improve lives. The company utilizes the Recursion OS, a platform that integrates diverse technologies to generate a vast proprietary dataset, leveraging machine-learning algorithms to explore relationships in biology and chemistry. Recursion conducts extensive experimental and computational operations, positioning itself as a leader in the TechBio space. The company is headquartered in Salt Lake City and has additional offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area.
YTD Price Performance: -5.13%
Average Trading Volume: 23,594,970
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.55B
For an in-depth examination of RXRX stock, go to TipRanks’ Stock Analysis page.